|1.||Oki, Shinji: 1 article (06/2007)|
|2.||Tomi, Chiharu: 1 article (06/2007)|
|3.||Kaieda, Shinjiro: 1 article (06/2007)|
|4.||Miyake, Sachiko: 1 article (06/2007)|
|5.||Yamamura, Takashi: 1 article (06/2007)|
06/01/2007 - "This study was designed to evaluate the protective effects of SGL-S23 in an effector phase of arthritis. "
06/01/2007 - "SGL-S23 strongly suppressed K/BxN serum transfer arthritis by inhibiting inflammatory cell infiltration and subsequent destruction of cartilage and bone. "
06/01/2007 - "Stimulation of invariant natural killer T (iNKT) cells with SGL-S23, a novel synthetic glycolipid analog of alpha-galactosylceramide with an elongated sphingosine chain, has been shown to strongly suppress K/BxN serum transfer arthritis. "